Fareston European Union - English - EMA (European Medicines Agency)

fareston

orion corporation - toremifene - breast neoplasms - endocrine therapy - first line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.fareston is not recommended for patients with estrogen receptor negative tumours.

Levodopa/Carbidopa/Entacapone Orion European Union - English - EMA (European Medicines Agency)

levodopa/carbidopa/entacapone orion

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - nervous system - levodopa/carbidopa/entacapone orion is indicated for the treatment of adult patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (ddc)-inhibitor treatment.

Comtan European Union - English - EMA (European Medicines Agency)

comtan

orion corporation - entacapone - parkinson disease - anti-parkinson drugs - entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.

Comtess European Union - English - EMA (European Medicines Agency)

comtess

orion corporation - entacapone - parkinson disease - anti-parkinson drugs - entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in patients with parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.

Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz) European Union - English - EMA (European Medicines Agency)

corbilta (previously levodopa/carbidopa/entacapone sandoz)

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - anti-parkinson drugs - corbilta is indicated for the treatment of adult patients with parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Entacapone Orion European Union - English - EMA (European Medicines Agency)

entacapone orion

orion corporation - entacapone - parkinson disease - anti-parkinson drugs - entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.

Stalevo European Union - English - EMA (European Medicines Agency)

stalevo

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - anti-parkinson drugs - stalevo is indicated for the treatment of adult patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (ddc)-inhibitor treatment.

Nyxoid European Union - English - EMA (European Medicines Agency)

nyxoid

mundipharma corporation (ireland) limited - naloxone hydrochloride dihydrate - opioid-related disorders - all other therapeutic products - nyxoid is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings.nyxoid is indicated in adults and adolescents aged 14 years and over.nyxoid is not a substitute for emergency medical care.

Dexdomitor European Union - English - EMA (European Medicines Agency)

dexdomitor

orion corporation - dexmedetomidine hydrochloride - psycholeptics - dogs; cats - noninvasive, mildly to moderately painful, procedures and examinations which require restraint, sedation and analgesia in dogs and cats.premedication in cats before induction and maintenance of general anaesthesia with ketamine.deep sedation and analgesia in dogs in concomitant use with butorphanol for medical and minor surgical procedures.premedication in dogs before induction and maintenance of general anaesthesia.

Imoxat European Union - English - EMA (European Medicines Agency)

imoxat

chanelle pharmaceuticals manufacturing ltd - imidacloprid, moxidectin - antiparasitic products, insecticides and repellents, macrocyclic lactones, milbemycins - cats; dogs; ferrets - for cats suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the treatment of ear mite infestation (otodectes cynotis),• the treatment of notoedric mange (notoedres cati),• the treatment of the lungworm eucoleus aerophilus (syn. capillaria aerophila) (adults),• the prevention of lungworm disease (l3/l4 larvae of aelurostrongylus abstrusus),• the treatment of the lungworm aelurostrongylus abstrusus (adults),• the treatment of the eye worm thelazia callipaeda (adults),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),• the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara cati and ancylostoma tubaeforme).the veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (fad). for ferrets suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis). for dogs suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the treatment of biting lice (trichodectes canis),• the treatment of ear mite infestation (otodectes cynotis), sarcoptic mange (caused by sarcoptes scabiei var. canis), demodicosis (caused by demodex canis),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),• the treatment of circulating microfilariae (dirofilaria immitis),• the treatment of cutaneous dirofilariosis (adult stages of dirofilaria repens)• the prevention of cutaneous dirofilariosis (l3 larvae of dirofilaria repens),• the reduction of circulating microfilariae (dirofilaria repens),• the prevention of angiostrongylosis (l4 larvae and immature adults of angiostrongylus vasorum),• the treatment of angiostrongylus vasorum and crenosoma vulpis,• the prevention of spirocercosis (spirocerca lupi),• the treatment of eucoleus (syn. capillaria) boehmi (adults),• the treatment of the eye worm thelazia callipaeda (adults),• the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara canis, ancylostoma caninum and uncinaria stenocephala, adults of toxascaris leonina and trichuris vulpis).the veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (fad).